Opinion|Videos|July 2, 2024
Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- A subcutaneous form of ocrelizumab may come to market later this year. How will you incorporate this into your treatment algorithms?
- Will payers evaluate coverage decisions for this therapy differently than the intravenous form?
Advertisement
Related to this article
Home-based oncology transforms practice transformation with clear bagging, protecting Medicare reimbursement, provider control, and lower costs for patients, health systems, and payers.
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
5